Kirill Pevzner
Founder & Chief Technical Officer Protai
Seminars
Wednesday 13th January 2027
Panel Discussion: Expanding the Druggable Universe & the Future of Rational Drug Design in an Era of AI, Structural Biology & Emerging Modalities
9:00 am
- Explore why complex, dynamic, and previously inaccessible targets have challenged traditional drug discovery approaches
- Discover how advances in structural biology, biophysics, computational chemistry, and AI are expanding the druggable proteome
- Understand how molecular glues, degraders, and other emerging modalities reshaping discovery portfolios are and required capabilities
- Identify which technologies are driving value today versus those likely to transform discovery over the next decade
- Learn how leading organisations are combining experimental and computational approaches to pursue challenging targets with greater confidence
Wednesday 13th January 2027
Panel Discussion: Building Trust in AI Predictions by Validation & Benchmarking
4:00 pm
- Establish rigorous validation frameworks that identify the 50% of AI outputs that are hallucinations, ensuring your teams trust and adopt computational tools rather than dismissing them due to poor early experiences
- Learn how to benchmark AI predictions against experimental data, understanding which use cases deliver value and which remain aspirational
- Discover strategies to educate scientific teams on AI capabilities and limitations, setting realistic expectations and driving productive adoption while avoiding the “magic bullet” trap
Thursday 14th January 2027
Unlocking Rational Design of Induced Proximity Drugs Through AI-Powered Structural Proteomics
12:00 pm
- Demonstrating how structural proteomics and AI can reveal the architecture and dynamics of induced proximity complexes that traditional structural approaches cannot capture
- Establishing a rational design framework for molecular glues and targeted protein degraders to improve potency, selectivity, and developability
- Showcasing how AI-guided structural insights accelerated Protai’s oncology pipeline, from protein complex modelling through in vivo efficacy and IND-enabling development
